Overview

First-in-Human Single and Multiple Dose of HL-400

Status:
RECRUITING

Trial end date:
2026-02-27

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.

Overview

First-in-Human Single and Multiple Dose of HL-400

Summary

Phase:

Details

Lead Sponsor: